ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

OBD Oxford Biodynamics Plc

8.10
-0.10 (-1.22%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biodynamics Plc LSE:OBD London Ordinary Share GB00BD5H8572 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -1.22% 8.10 8.10 8.48 8.50 8.00 8.00 921,776 16:26:34
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.34M -10.83M -0.0535 -1.51 16.39M

Oxford BioDynamics PLC Director/PDMR Shareholding (5028W)

18/04/2023 7:00am

UK Regulatory


Oxford Biodynamics (LSE:OBD)
Historical Stock Chart


From Apr 2022 to Apr 2024

Click Here for more Oxford Biodynamics Charts.

TIDMOBD

RNS Number : 5028W

Oxford BioDynamics PLC

18 April 2023

Oxford BioDynamics Plc

Oxford BioDynamics Plc

( " OBD " or the " Company " and, together with its subsidiaries, the " Group " )

PDMR Dealing / Grant of Share Options

18 April 2023 - Oxford, UK - Oxford BioDynamics Plc (AIM: OBD), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch(R) 3D genomics platform, announces that it has granted a total of 863,561 options over its ordinary shares of 1 pence each ("Ordinary Shares"), to certain Group employees, including 733,561 options to Chief Executive Officer, Dr Jon Burrows. The options were granted under the Company's 2016 Employee Share Option Plan with an exercise price of 15.6p per share.

One-third of the options granted to Dr Burrows will vest and become exercisable on each of 23 March 2024, 23 March 2025 and 23 March 2026. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.

Following this grant, Dr Jon Burrows, holds options over Ordinary Shares and is interested in Ordinary Shares as follows:

 
                    Total number    Ordinary Shares held 
                 of options over 
                 Ordinary Shares 
                                    Number    % of current 
                                              issued share 
                                                   capital 
                                  --------  -------------- 
 Jon Burrows           2,623,714   300,000            0.2% 
               -----------------  --------  -------------- 
 

The information set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.

 
      Details of the person discharging managerial responsibilities/person 
  1    closely associated 
 a)   Name                        Jon Burrows 
     --------------------------  --------------------------------------------- 
      Reason for the notification 
  2 
     ------------------------------------------------------------------------- 
 a)   Position/status             Director/PDMR 
     --------------------------  --------------------------------------------- 
 b)   Initial notification/       Initial notification 
       Amendment 
     --------------------------  --------------------------------------------- 
      Details of the issuer, emission allowance market participant, 
  3    auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------- 
 a)   Name                        Oxford BioDynamics Plc 
     --------------------------  --------------------------------------------- 
 b)   LEI                         2138005Y1TK258O5U928 
     --------------------------  --------------------------------------------- 
      Details of the transaction(s): section to be repeated for 
  4    (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ------------------------------------------------------------------------- 
 a)   Description of the          Ordinary Shares of 1 pence each 
       financial instrument, 
       type of instrument          ISIN: GB00BD5H8572 
       Identification code 
     --------------------------  --------------------------------------------- 
 b)   Nature of the transaction   Grant of share options 
     --------------------------  --------------------------------------------- 
 c)   Price(s) and volume(s)      733,561 Ordinary Shares at an exercise price 
                                   of 15.6 pence per share 
     --------------------------  --------------------------------------------- 
 d)   Aggregated information      N/A 
       - Aggregated volume 
       - Price 
     --------------------------  --------------------------------------------- 
 e)   Date of the transaction     17 April 2023 
     --------------------------  --------------------------------------------- 
 f)   Place of the transaction    Outside a trading venue 
     --------------------------  --------------------------------------------- 
 

For further details please contact:

 
 Oxford BioDynamics Plc                              Tel: +44 (0)1865 518910 
  Jon Burrows, CEO 
  Paul Stockdale, CFO 
 Shore Capital                                      Tel: +44 (0)20 7408 4090 
  Nominated Adviser and Broker 
  Stephane Auton 
  John More 
 
   Instinctif Partners                              Tel: +44 (0)20 7457 2020 
   Melanie Toyne-Sewell / Rozi Morris /     OxfordBioDynamics@instinctif.com 
   Adam Loudon 
 

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch(R) CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch(R) Explorer Array Kit .

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch(R), which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .

About EpiSwitch(R)

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch(R) can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch(R) is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch(R) data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFETSFIDLIV

(END) Dow Jones Newswires

April 18, 2023 02:00 ET (06:00 GMT)

1 Year Oxford Biodynamics Chart

1 Year Oxford Biodynamics Chart

1 Month Oxford Biodynamics Chart

1 Month Oxford Biodynamics Chart

Your Recent History

Delayed Upgrade Clock